Navigation Links
New Study Released Today Showed Patients With Deadly Form of Lung Cancer Lived Longer Without Disease Worsening
Date:6/5/2011

INDIANAPOLIS, June 5, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that PARAMOUNT, its Phase III study evaluating ALIMTA® (pemetrexed for injection) in the continuation maintenance setting, met its primary endpoint of progression-free survival, or the time a patient is alive without their disease worsening, for patients with a specific type of lung cancer called advanced nonsquamous non-small cell lung cancer (NSCLC).

"Continuation maintenance" treatment is when one of the same medicines used in first-line treatment setting is continued as maintenance therapy in an effort to control the cancer.  

Results from the study will be presented on Sunday, June 5 at 11:30 a.m. CDT during the Lung Cancer Oral Abstract Session (Abstract #CRA7510) at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill.  Lilly will present overall survival results from PARAMOUNT at a medical meeting in the future.

PARAMOUNT is the second study to evaluate the use of ALIMTA as a maintenance therapy in patients with advanced nonsquamous NSCLC, and the first study to evaluate the use of continuation maintenance with ALIMTA(1) following first-line ALIMTA plus cisplatin therapy.

Results of this multicenter, double-blind trial demonstrated the median progression-free survival measured from randomization (after first-line treatment) was 3.9 months on the ALIMTA arm as compared to 2.6 months on the placebo arm with a hazard ratio of 0.64.  Said another way, the study showed that ALIMTA continuation maintenance arm resulted in a 36 percent improvement of survival without disease worsening over the placebo arm. The maintenance disease control rate, or the percentage of patients achieving either a response or stable disease first measured at 6 weeks post-randomization was 71.8 percent (2.8%/69.0%) on the ALIMTA
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Finds Treatment with Metreleptin Improved Diabetes and Lipid Control in Patients with Partial Lipodystrophy
2. New Study Questions Ability of Radiology Benefit Managers to Lower Costs
3. A Recent Study by ITGs Majestic Market Research Indicates a Strong Launch for Gilenya in Spite of Its Time-Consuming Initiation Process
4. Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization
5. Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients
6. Robotic Prostatectomy Expert Dr. David Samadi on a High Impact Study Advocating Aggressive Early-Stage Prostate Cancer Treatment
7. All-Oral Combination Study with PSI-7977 for HCV Genotypes 1, 2 and 3 Initiated
8. Pivotal Phase 3 Study Published in The New England Journal of Medicine (NEJM) Finds Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer is Significantly Improved with ZYTIGA™ (abiraterone acetate)
9. Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
10. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
11. U-M Study: Children Dependent on Long-Term Mechanical Ventilation Require Longer, More Expensive Hospital Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... NEWS, Virginia , 11. Juli ... Hersteller von Kameras für die molekulare ... (MBI/BSGI), hat heute die CE-Zulassung für ... dem CE-Zeichen kann Dilon das Produkt ... Vertriebsbereich auf den Großteil der europäischen ...
(Date:7/10/2014)... Yesterday, former Congressman Patrick Kennedy ... facility. Rep. Kennedy and Dick Moberg ... research in neurological disease and treatment. ... Garen Staglin , created One Mind, a ... that will radically accelerate the development and implementation ...
(Date:7/10/2014)... 2014   LabStyle Innovations Corp . (OTCQB:DRIO), developer ... the appointment of Professor Richard B. Stone ... of Directors. Prof. Stone brings over ... LabStyle as an entrepreneur, venture capitalist public, company ... expert. He currently serves on the board of ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4
... Heska Corporation (Nasdaq: HSKA ) announces the following Webcast: ... Quarter 2011 Earnings Conference Call on the Web When: Monday, ... (click on the Q3 2011 Earnings Call link on the front ... Simply log on to the web at the address above.   ...
... premium provider of new and refurbished ultrasound solutions, today announced ... GE E8/E9 transducers.  MedPro is the first and only provider ... ultrasound systems and has been offering this repair in partnership ... six months. In addition to the new E8/E9 ...
Cached Medicine Technology:Webcast Alert: Heska Announces Third Quarter 2011 Earnings Conference Call Webcast 2MedPro Imaging to Repair GE E8/E9 Ultrasound Transducers 2
(Date:7/13/2014)... 2014 Recently, iFitDress.com, one of the ... its beautiful collection of brown evening dresses ... now available at discounted prices, up to 50% off. ... high quality; they are carefully made according to most ... gowns, iFitDress.com also offers pretty accessories: wedding shoes, dancing ...
(Date:7/13/2014)... to get the best treatment and variations in the ... survival for blood cancer patients still varies widely between ... of survival in European adults to date, published in ... is that 5-year survival for most cancers of the ... likely reflecting the approval of new targeted drugs in ...
(Date:7/13/2014)... Nature Genetics identifies a novel genetic and ... esophagitis (EoE), opening up potential new therapeutic strategies ... , EoE is a chronic inflammatory disorder of ... hypersensitivity to certain foods and an over-accumulation in ... (part of the body,s immune system). EoE can ...
(Date:7/13/2014)... 2014 Victorian Hotel has recently announced ... rental of bikes for its "Cycle the City" program, ... to tour the area using a rental bicycle, available ... love to call Vancouver home, as it is a ... and picturesque journeys through the countryside. Vancouver hotel rooms ...
(Date:7/13/2014)... 13, 2014 Advanced boilers are ... least amount of fossil fuels, produce high-capacity power, ... to increased global warming and climate change concerns, ... reduce harmful gas emissions and pollutants coming from ... in the global advance boilers market., The global ...
Breaking Medicine News(10 mins):Health News:2014 Brown Evening Dresses Added To iFitDress.com 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 3Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:Victorian Hotel Creates Excitement by Adding "Cycle the City" Bike Rentals for Its Vancouver Hotel Rooms 2Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 2Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 3
... Nov. 6 Par,Pharmaceutical Companies, Inc. (NYSE: PRX ) ... Third Quarter and Nine Month Results, For the ... $149.0 million and net income of $1.7 million, or $0.05 ... million,and net income of $1.3 million, or $0.04 per diluted ...
... Atlanta, Ga. November 06, 2008 Down syndrome, ... in approximately 1-in-700 births in the United States. Additionally, ... lost before birth. , The Centers for Disease Control ... convened a meeting of experts to review the current ...
... ResMed Inc. (NYSE: RMD ),today announced record revenue ... Revenue for the quarter was $217.9 million, a 17%,increase ... current,quarter, income from operations was $36.6 million and net ... respectively, compared to the quarter,ended September 30, 2007. Diluted ...
... cosmetics or a workplace chemical are often to blame, ... A wide variety of substances can cause the skin ... effectively managed with proper diagnosis and treatment, experts say. ... of the skin resulting from contact with a chemical, ...
... MVP Health Care, a leading,regional not-for-profit health ... Vermont and New Hampshire, has selected IncentOne, the ... to MVP and,Preferred Care health plan members through ... Care health plans that utilize the "WellStyle Extras",option, ...
... chosen by their teachers from four counties, San,Bernardino, Riverside, ... BERNARDINO, Calif., Nov. 6 On Sunday, November 9,2008 ... philanthropic,arm of Stater Bros. Markets, in conjunction with KFRG ... to community children on the field,of the Arrowhead Credit ...
Cached Medicine News:Health News:Par Pharmaceutical Reports Third Quarter 2008 Results 2Health News:Par Pharmaceutical Reports Third Quarter 2008 Results 3Health News:Par Pharmaceutical Reports Third Quarter 2008 Results 4Health News:Par Pharmaceutical Reports Third Quarter 2008 Results 5Health News:Par Pharmaceutical Reports Third Quarter 2008 Results 6Health News:Par Pharmaceutical Reports Third Quarter 2008 Results 7Health News:Par Pharmaceutical Reports Third Quarter 2008 Results 8Health News:Par Pharmaceutical Reports Third Quarter 2008 Results 9Health News:ResMed Inc Announces Record Financial Results for the Quarter Ended September 30, 2008 2Health News:ResMed Inc Announces Record Financial Results for the Quarter Ended September 30, 2008 3Health News:ResMed Inc Announces Record Financial Results for the Quarter Ended September 30, 2008 4Health News:ResMed Inc Announces Record Financial Results for the Quarter Ended September 30, 2008 5Health News:ResMed Inc Announces Record Financial Results for the Quarter Ended September 30, 2008 6Health News:ResMed Inc Announces Record Financial Results for the Quarter Ended September 30, 2008 7Health News:Dermatitis Can Have Many Causes 2Health News:MVP Health Care and IncentOne Partner to Provide Member Incentives for MVP and Preferred Care 'WellStyle Extras' Program 2Health News:Stater Bros. Charities, KFRG Radio Stations and Loma Linda University Children's Hospital Will Present More Than 1,100 Brand-New Bikes to 4th Grade Students! 2
... Saturated Swabsticks are packaged ... foil-laminated pouches. Each 4 ... with precisely the correct ... package is terminally sterilized, ...
... alcohol and 10% povidone iodine formulated ... a barrier on the skin. The ... the povidone iodine, giving persistent protection ... catheter related infections for up to ...
... Aplicare's Saturated Swabsticks ... open, single-use foil-laminated pouches. ... is saturated with precisely ... solution. Each package is ...
... Aplicare's saturated swabsticks are packaged in easy ... inch swabstick is saturated with precisely the ... Gel Swabstick is saturated with a multi-purpose ... gel is also approved for venipuncture site ...
Medicine Products: